CNSP on Nasdaq
CNS Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative | $6.2M | $5.6M |
| Research and development | $9.8M | $9.3M |
| Total operating expenses | $16.0M | $14.9M |
| Loss from operations | -$16.0M | -$14.9M |
| Other expense | -$2.6K | $0 |
| Interest income | $153.8K | $60.3K |
| Interest expense | -$15.2K | -$16.1K |
| Total other income (expense) | $136.0K | $44.1K |
| Net loss | -$15.9M | -$14.9M |
| Loss per share - basic | -$35.75 | -$466.89 |
| Loss per share - diluted | -$35.75 | -$466.89 |
| Weighted average shares outstanding - basic | 443.4K shares | 31.8K shares |
| Weighted average shares outstanding - diluted | 443.4K shares | 31.8K shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2025-11-30 | 2025-07-31 |
|---|---|---|---|
| Cash and cash equivalents | $7.2M | ||
| Deferred offering costs | $45.5K | ||
| Subscription receivable | $0 | ||
| Prepaid expenses and other current assets | $856.3K | ||
| Total current assets | $8.1M | ||
| Prepaid expenses, net of current portion | $503.0K | ||
| Property and equipment, net | $17.7K | ||
| Total noncurrent assets | $520.7K | ||
| Total Assets | $8.6M | ||
| Accounts payable and accrued expenses | $3.8M | ||
| Notes payable | $328.6K | ||
| Total current liabilities | $4.1M | ||
| Total Liabilities | $4.1M | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding | $0 | ||
| Common stock, $0.001 par value, 300,000,000 shares authorized and 632,516 and 117,796 shares issued and outstanding, respectively | $633 | ||
| Additional paid-in capital | $104.8M | ||
| Accumulated deficit | -$100.3M | ||
| Total Stockholders' Equity (Deficit) | $4.5M | ||
| Total Liabilities and Stockholders' Equity (Deficit) | $8.6M | ||
| Preferred stock, par value | $0.00 | ||
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares | 416.7K shares |
| Preferred stock, shares issued | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | ||
| Common stock, par value | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | 25.0M shares |
| Common stock, shares issued | 632.5K shares | ||
| Common stock, shares outstanding | 632.5K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$15.9M | -$14.9M |
| Stock-based compensation | $187.7K | $839.0K |
| Depreciation | $3.9K | $3.3K |
| Common stock issued for license agreement | $0 | $596.3K |
| Loss (gain) on disposal of fixed assets | $2.6K | -$190 |
| Prepaid expenses and other current assets | $302.8K | -$60.0K |
| Accounts payable and accrued expenses | $1.5M | -$3.6M |
| Net cash used in operating activities | -$13.8M | -$17.1M |
| Purchase of property and equipment | -$18.2K | -$4.2K |
| Net cash used in investing activities | -$18.2K | -$4.2K |
| Payments of deferred offering costs | -$64.1K | -$66.8K |
| Payments on notes payable | -$297.6K | -$300.8K |
| Stock repurchased during stock split rounding | -$2.0K | $0 |
| Proceeds from subscription receivable | $882.5K | $0 |
| Proceeds from exercise of warrants | $3.6K | $21.3K |
| Proceeds from sale of common stock | $14.0M | $23.4M |
| Net cash provided by financing activities | $14.6M | $23.0M |
| Net change in cash and cash equivalents | $739.6K | $5.9M |
| Cash paid for interest | $15.3K | $13.6K |
| Cash paid for income taxes | $0 | $0 |
| Prepaid expense financed with note payable | $360.2K | $326.1K |
| Reclassification of deferred offering costs to equity | $39.2K | $249.0K |
| Common stock issued for subscription receivable | $0 | $882.5K |
| Stock issued for stock split rounding | $0 | $2 |
Recent filings
- Oct 2, 20268-K
- Aug 25, 2026DEFA14A
- Aug 21, 2026DEF 14A DEFINITIVE NOTICE AND PROXY STATEMENT
- Aug 18, 20264
- Aug 18, 20263
- Aug 18, 20264
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 202610-Q FORM 10-Q FOR JUN 2026
- Jul 2, 20268-K
- May 26, 2026424B3 424B3 PROSPECTUS
- May 26, 2026EFFECT
- May 22, 2026UPLOAD
- May 22, 2026CORRESP
- May 20, 20264
- May 19, 2026S-3 FORM S-3 REGISTRATION STATEMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10